ALK and non-small cell lung carcinoma: Additionally, this analysis demonstrated consistent hepatotoxicity signals across all five ALK-TKIs, aligning with a meta-analysis reporting elevated hepatotoxicity risks in NSCLC patients treated with ALK inhibitors (pooled incidence: 26% for ALT elevation and 23.2% for AST elevation) [32].